Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Frailty | 6 | 2024 | 79 | 3.430 |
Why?
|
| Lung Transplantation | 5 | 2024 | 312 | 2.370 |
Why?
|
| Solitary Pulmonary Nodule | 3 | 2020 | 139 | 1.780 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 2368 | 1.590 |
Why?
|
| Pneumonectomy | 6 | 2024 | 211 | 1.520 |
Why?
|
| Perfusion | 5 | 2024 | 253 | 1.210 |
Why?
|
| Kidney Transplantation | 5 | 2024 | 854 | 1.150 |
Why?
|
| Frail Elderly | 2 | 2024 | 80 | 1.090 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 414 | 1.020 |
Why?
|
| Tracheal Stenosis | 2 | 2021 | 25 | 0.920 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2024 | 55 | 0.890 |
Why?
|
| Antibody Formation | 2 | 2021 | 171 | 0.880 |
Why?
|
| Antibodies, Viral | 3 | 2021 | 311 | 0.840 |
Why?
|
| Lung | 7 | 2024 | 1292 | 0.830 |
Why?
|
| Graft Survival | 4 | 2022 | 907 | 0.830 |
Why?
|
| Graft Rejection | 5 | 2022 | 1075 | 0.820 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 15 | 0.800 |
Why?
|
| Postoperative Complications | 6 | 2024 | 2299 | 0.800 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 465 | 0.770 |
Why?
|
| Tracheal Neoplasms | 1 | 2021 | 8 | 0.750 |
Why?
|
| Tracheostomy | 1 | 2021 | 46 | 0.720 |
Why?
|
| Patient Selection | 3 | 2020 | 678 | 0.720 |
Why?
|
| Symptom Assessment | 1 | 2020 | 66 | 0.700 |
Why?
|
| Sarcopenia | 1 | 2019 | 13 | 0.680 |
Why?
|
| Intubation, Intratracheal | 1 | 2021 | 147 | 0.670 |
Why?
|
| Leukocytes | 2 | 2022 | 209 | 0.640 |
Why?
|
| Histocompatibility | 2 | 2015 | 65 | 0.620 |
Why?
|
| Bioengineering | 2 | 2014 | 14 | 0.600 |
Why?
|
| Mediastinal Neoplasms | 1 | 2018 | 46 | 0.590 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 425 | 0.580 |
Why?
|
| Pulmonary Artery | 1 | 2019 | 320 | 0.570 |
Why?
|
| Angiography | 1 | 2018 | 208 | 0.570 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2017 | 30 | 0.560 |
Why?
|
| Aged | 12 | 2024 | 19212 | 0.560 |
Why?
|
| Bronchoscopy | 2 | 2021 | 162 | 0.550 |
Why?
|
| Humans | 37 | 2024 | 89785 | 0.530 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 471 | 0.530 |
Why?
|
| Body Mass Index | 1 | 2019 | 775 | 0.530 |
Why?
|
| Retrospective Studies | 11 | 2024 | 9159 | 0.520 |
Why?
|
| Composite Tissue Allografts | 1 | 2015 | 7 | 0.510 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 38 | 0.500 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2019 | 2676 | 0.490 |
Why?
|
| Organ Preservation | 4 | 2024 | 119 | 0.490 |
Why?
|
| Skin Transplantation | 1 | 2015 | 184 | 0.460 |
Why?
|
| Transplantation, Heterologous | 1 | 2014 | 368 | 0.440 |
Why?
|
| Male | 18 | 2024 | 42582 | 0.420 |
Why?
|
| Immune Tolerance | 1 | 2015 | 341 | 0.420 |
Why?
|
| Tissue Engineering | 1 | 2014 | 191 | 0.400 |
Why?
|
| Tissue Donors | 5 | 2022 | 502 | 0.390 |
Why?
|
| Female | 15 | 2024 | 46494 | 0.380 |
Why?
|
| Massachusetts | 2 | 2021 | 33 | 0.360 |
Why?
|
| Kidney | 2 | 2024 | 1148 | 0.360 |
Why?
|
| Middle Aged | 9 | 2024 | 26080 | 0.350 |
Why?
|
| Heart Transplantation | 4 | 2018 | 717 | 0.350 |
Why?
|
| Postoperative Care | 2 | 2024 | 231 | 0.320 |
Why?
|
| Tissue and Organ Procurement | 3 | 2022 | 357 | 0.320 |
Why?
|
| Anastomosis, Surgical | 2 | 2021 | 275 | 0.320 |
Why?
|
| Swine, Miniature | 3 | 2018 | 50 | 0.290 |
Why?
|
| Swine | 4 | 2018 | 590 | 0.280 |
Why?
|
| Survival Rate | 2 | 2021 | 1890 | 0.260 |
Why?
|
| Antibodies, Neutralizing | 3 | 2021 | 123 | 0.260 |
Why?
|
| Quality of Life | 2 | 2024 | 1674 | 0.250 |
Why?
|
| Treatment Outcome | 5 | 2022 | 8243 | 0.240 |
Why?
|
| Transplant Recipients | 2 | 2023 | 138 | 0.240 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2024 | 34 | 0.240 |
Why?
|
| Codon | 1 | 2024 | 123 | 0.240 |
Why?
|
| Adult | 7 | 2024 | 26767 | 0.230 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 44 | 0.230 |
Why?
|
| Metabolomics | 1 | 2024 | 76 | 0.220 |
Why?
|
| Exercise Therapy | 1 | 2024 | 82 | 0.220 |
Why?
|
| Cytokines | 3 | 2022 | 811 | 0.220 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3663 | 0.220 |
Why?
|
| Elective Surgical Procedures | 1 | 2024 | 128 | 0.210 |
Why?
|
| High-Throughput Screening Assays | 1 | 2023 | 58 | 0.210 |
Why?
|
| Immunoglobulin G | 2 | 2024 | 469 | 0.210 |
Why?
|
| Cell Culture Techniques | 1 | 2023 | 194 | 0.210 |
Why?
|
| Geriatric Assessment | 1 | 2024 | 182 | 0.200 |
Why?
|
| Pyridones | 1 | 2022 | 56 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2022 | 118 | 0.190 |
Why?
|
| Imidazoles | 1 | 2022 | 140 | 0.190 |
Why?
|
| Laryngostenosis | 1 | 2021 | 18 | 0.190 |
Why?
|
| Reoperation | 2 | 2021 | 604 | 0.190 |
Why?
|
| Immunodominant Epitopes | 1 | 2021 | 20 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 147 | 0.190 |
Why?
|
| Esophagectomy | 1 | 2021 | 91 | 0.180 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.180 |
Why?
|
| Respiratory System | 1 | 2021 | 117 | 0.180 |
Why?
|
| Exercise | 1 | 2024 | 326 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2024 | 333 | 0.180 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 476 | 0.180 |
Why?
|
| United States | 2 | 2024 | 7083 | 0.170 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 46 | 0.170 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 740 | 0.170 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 125 | 0.170 |
Why?
|
| Morbidity | 1 | 2019 | 149 | 0.160 |
Why?
|
| Transcriptome | 2 | 2021 | 660 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 523 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 330 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 237 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2019 | 98 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2021 | 258 | 0.150 |
Why?
|
| Bronchi | 1 | 2019 | 230 | 0.150 |
Why?
|
| Electromagnetic Phenomena | 1 | 2017 | 18 | 0.140 |
Why?
|
| Brain Death | 1 | 2018 | 83 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2019 | 344 | 0.140 |
Why?
|
| Transplantation Tolerance | 1 | 2018 | 138 | 0.130 |
Why?
|
| Time Factors | 2 | 2015 | 5350 | 0.130 |
Why?
|
| Heart | 2 | 2021 | 575 | 0.130 |
Why?
|
| Ischemia | 1 | 2018 | 252 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2019 | 1496 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2018 | 395 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 419 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1134 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2015 | 70 | 0.120 |
Why?
|
| Transplantation Chimera | 1 | 2015 | 81 | 0.120 |
Why?
|
| Major Histocompatibility Complex | 1 | 2015 | 84 | 0.120 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 137 | 0.120 |
Why?
|
| Jejunal Diseases | 1 | 2014 | 10 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2648 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1066 | 0.120 |
Why?
|
| Ileal Diseases | 1 | 2014 | 26 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 2000 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2018 | 264 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1175 | 0.120 |
Why?
|
| Intestinal Perforation | 1 | 2014 | 36 | 0.120 |
Why?
|
| Abscess | 1 | 2014 | 94 | 0.120 |
Why?
|
| Diverticulum | 1 | 2014 | 45 | 0.120 |
Why?
|
| Allografts | 1 | 2015 | 184 | 0.120 |
Why?
|
| Isoantibodies | 1 | 2015 | 120 | 0.120 |
Why?
|
| Mutation | 2 | 2024 | 4164 | 0.120 |
Why?
|
| Models, Animal | 1 | 2015 | 277 | 0.110 |
Why?
|
| Risk Factors | 2 | 2024 | 5539 | 0.110 |
Why?
|
| Public Health | 1 | 2014 | 140 | 0.110 |
Why?
|
| Animals | 6 | 2024 | 27512 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2019 | 2886 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 96 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2505 | 0.100 |
Why?
|
| Hospitalists | 1 | 2013 | 139 | 0.090 |
Why?
|
| Cross Reactions | 2 | 2021 | 109 | 0.090 |
Why?
|
| Hospital Mortality | 1 | 2013 | 403 | 0.090 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2887 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2013 | 397 | 0.090 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 156 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 798 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 889 | 0.080 |
Why?
|
| V(D)J Recombination | 1 | 2024 | 11 | 0.060 |
Why?
|
| Complementarity Determining Regions | 1 | 2024 | 25 | 0.060 |
Why?
|
| Endothelin-1 | 2 | 2015 | 40 | 0.060 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2024 | 133 | 0.060 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2024 | 110 | 0.060 |
Why?
|
| Adenosine Triphosphate | 2 | 2015 | 316 | 0.060 |
Why?
|
| HIV-1 | 1 | 2024 | 167 | 0.060 |
Why?
|
| Principal Component Analysis | 1 | 2024 | 161 | 0.060 |
Why?
|
| Small Molecule Libraries | 1 | 2023 | 65 | 0.050 |
Why?
|
| Zebrafish | 1 | 2024 | 320 | 0.050 |
Why?
|
| Gastric Emptying | 1 | 2021 | 25 | 0.050 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2021 | 8 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 776 | 0.050 |
Why?
|
| Receptor, Endothelin A | 1 | 2021 | 21 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2021 | 16 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2021 | 80 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 629 | 0.050 |
Why?
|
| Sexism | 1 | 2021 | 54 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 140 | 0.050 |
Why?
|
| Stomach | 1 | 2021 | 111 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 222 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 145 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 66 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 370 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 860 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 254 | 0.040 |
Why?
|
| Bioethics | 1 | 2020 | 35 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 135 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2021 | 164 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 234 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 98 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 241 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 260 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 209 | 0.040 |
Why?
|
| Living Donors | 1 | 2022 | 339 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 284 | 0.040 |
Why?
|
| Cell Line | 1 | 2023 | 2495 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 434 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1394 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 551 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 490 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 1211 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 277 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 1184 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2315 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1598 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 778 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1451 | 0.030 |
Why?
|
| Presumed Consent | 1 | 2014 | 1 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 56 | 0.030 |
Why?
|
| Disaccharides | 1 | 2014 | 23 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2021 | 1227 | 0.030 |
Why?
|
| Electrolytes | 1 | 2014 | 52 | 0.030 |
Why?
|
| Pulsatile Flow | 1 | 2014 | 50 | 0.030 |
Why?
|
| Organ Preservation Solutions | 1 | 2014 | 31 | 0.030 |
Why?
|
| Mannitol | 1 | 2014 | 50 | 0.030 |
Why?
|
| Histidine | 1 | 2014 | 56 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2014 | 51 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 88 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 136 | 0.030 |
Why?
|
| Glutathione | 1 | 2014 | 108 | 0.030 |
Why?
|
| Cold Temperature | 1 | 2014 | 160 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2765 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2014 | 142 | 0.030 |
Why?
|
| Myocardium | 1 | 2015 | 572 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 314 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4320 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 11846 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 607 | 0.020 |
Why?
|
| Oxygen | 1 | 2014 | 745 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1717 | 0.020 |
Why?
|